SAN DIEGO--(BUSINESS WIRE)--Cardium Therapeutics (AMEX:CXM) and its subsidiary InnerCool Therapies today announced the completion of a $5 million commercial credit facility with Life Sciences Capital to support the launch of InnerCool’s new product lines for patient temperature modulation and other ongoing product development activities.
